Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Takafumi Yamamoto; Takanori Ito; Tetsunari Hase; Masatoshi Ishigami; Kazuyuki Mizuno; Kenta Yamamoto; Norihiro Imai; Yoji Ishizu; Takashi Honda; Hirofumi Shibata; Takahiro Hatta; Naoyuki Yogo; Satoshi Yasuda; Hidenori Toyoda; Takashi Abe; Hiroki Kawashima; Naozumi Hashimoto; Mitsuhiro Fujishiro

doi:10.1080/07357907.2021.1994586

Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Takafumi Yamamoto
, Takanori Ito
, Tetsunari Hase
, Masatoshi Ishigami
, Kazuyuki Mizuno
, Kenta Yamamoto
, Norihiro Imai
, Yoji Ishizu
, Takashi Honda
, Hirofumi Shibata
, Takahiro Hatta
, Naoyuki Yogo
, Satoshi Yasuda
, Hidenori Toyoda
, Takashi Abe
, Hiroki Kawashima
, Naozumi Hashimoto
, Mitsuhiro Fujishiro

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

17 被引用数 (Scopus)

抄録

It remains unclear whether severe liver immune-related adverse events (liver-irAEs) can affect the prognosis in nonsmall cell lung carcinoma (NSCLC) patients. Of the 365 NSCLC patients treated with immune checkpoint inhibitors (ICIs), 19 suffered from severe liver-irAEs (grade ≥3). The median time-to-onset of liver-irAEs was 53 days postinjection of the first ICI. The progression-free survival and overall survival of the liver-irAEs group (median 69 and 262 days, respectively) were significantly worse than the nonliver-irAEs group (128 and 722 days; P = 0.010 and P = 0.007; respectively). In conclusion, liver-irAEs were associated with poor prognosis in NSCLC patients.

本文言語	英語
ページ（範囲）	189-198
ページ数	10
ジャーナル	Cancer Investigation
巻	40
号	2
DOI	https://doi.org/10.1080/07357907.2021.1994586
出版ステータス	出版済み - 2022
外部発表	はい

All Science Journal Classification (ASJC) codes

腫瘍学
癌研究

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1080/07357907.2021.1994586

他のファイルとリンク

フィンガープリント

「Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Yamamoto, T., Ito, T., Hase, T., Ishigami, M., Mizuno, K., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Shibata, H., Hatta, T., Yogo, N., Yasuda, S., Toyoda, H., Abe, T., Kawashima, H., Hashimoto, N., & Fujishiro, M. (2022). Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancer Investigation, 40(2), 189-198. https://doi.org/10.1080/07357907.2021.1994586

@article{e29600268e0d4377beca98baaf57aeb0,

title = "Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors",

abstract = "It remains unclear whether severe liver immune-related adverse events (liver-irAEs) can affect the prognosis in nonsmall cell lung carcinoma (NSCLC) patients. Of the 365 NSCLC patients treated with immune checkpoint inhibitors (ICIs), 19 suffered from severe liver-irAEs (grade ≥3). The median time-to-onset of liver-irAEs was 53 days postinjection of the first ICI. The progression-free survival and overall survival of the liver-irAEs group (median 69 and 262 days, respectively) were significantly worse than the nonliver-irAEs group (128 and 722 days; P = 0.010 and P = 0.007; respectively). In conclusion, liver-irAEs were associated with poor prognosis in NSCLC patients.",

author = "Takafumi Yamamoto and Takanori Ito and Tetsunari Hase and Masatoshi Ishigami and Kazuyuki Mizuno and Kenta Yamamoto and Norihiro Imai and Yoji Ishizu and Takashi Honda and Hirofumi Shibata and Takahiro Hatta and Naoyuki Yogo and Satoshi Yasuda and Hidenori Toyoda and Takashi Abe and Hiroki Kawashima and Naozumi Hashimoto and Mitsuhiro Fujishiro",

note = "Publisher Copyright: {\textcopyright} 2021 Taylor \& Francis Group, LLC.",

year = "2022",

doi = "10.1080/07357907.2021.1994586",

language = "English",

volume = "40",

pages = "189--198",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Taylor \& Francis Group LLC Philadelphia",

number = "2",

}

Yamamoto, T, Ito, T, Hase, T, Ishigami, M, Mizuno, K, Yamamoto, K, Imai, N, Ishizu, Y, Honda, T, Shibata, H, Hatta, T, Yogo, N, Yasuda, S, Toyoda, H, Abe, T, Kawashima, H, Hashimoto, N & Fujishiro, M 2022, 'Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors', Cancer Investigation, vol. 40, no. 2, pp. 189-198. https://doi.org/10.1080/07357907.2021.1994586

TY - JOUR

T1 - Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

AU - Yamamoto, Takafumi

AU - Ito, Takanori

AU - Hase, Tetsunari

AU - Ishigami, Masatoshi

AU - Mizuno, Kazuyuki

AU - Yamamoto, Kenta

AU - Imai, Norihiro

AU - Ishizu, Yoji

AU - Honda, Takashi

AU - Shibata, Hirofumi

AU - Hatta, Takahiro

AU - Yogo, Naoyuki

AU - Yasuda, Satoshi

AU - Toyoda, Hidenori

AU - Abe, Takashi

AU - Kawashima, Hiroki

AU - Hashimoto, Naozumi

AU - Fujishiro, Mitsuhiro

PY - 2022

Y1 - 2022

N2 - It remains unclear whether severe liver immune-related adverse events (liver-irAEs) can affect the prognosis in nonsmall cell lung carcinoma (NSCLC) patients. Of the 365 NSCLC patients treated with immune checkpoint inhibitors (ICIs), 19 suffered from severe liver-irAEs (grade ≥3). The median time-to-onset of liver-irAEs was 53 days postinjection of the first ICI. The progression-free survival and overall survival of the liver-irAEs group (median 69 and 262 days, respectively) were significantly worse than the nonliver-irAEs group (128 and 722 days; P = 0.010 and P = 0.007; respectively). In conclusion, liver-irAEs were associated with poor prognosis in NSCLC patients.

AB - It remains unclear whether severe liver immune-related adverse events (liver-irAEs) can affect the prognosis in nonsmall cell lung carcinoma (NSCLC) patients. Of the 365 NSCLC patients treated with immune checkpoint inhibitors (ICIs), 19 suffered from severe liver-irAEs (grade ≥3). The median time-to-onset of liver-irAEs was 53 days postinjection of the first ICI. The progression-free survival and overall survival of the liver-irAEs group (median 69 and 262 days, respectively) were significantly worse than the nonliver-irAEs group (128 and 722 days; P = 0.010 and P = 0.007; respectively). In conclusion, liver-irAEs were associated with poor prognosis in NSCLC patients.

UR - https://www.scopus.com/pages/publications/85120041816

UR - https://www.scopus.com/pages/publications/85120041816#tab=citedBy

U2 - 10.1080/07357907.2021.1994586

DO - 10.1080/07357907.2021.1994586

M3 - Article

C2 - 34658277

AN - SCOPUS:85120041816

SN - 0735-7907

VL - 40

SP - 189

EP - 198

JO - Cancer Investigation

JF - Cancer Investigation

IS - 2

ER -